June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
L. D,
Author:
L. K C,
Author:
L. K N,
Author:
La Cava, P.

PS1362 TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO-1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN-REGULATES CD38 IN MULTIPLE MYELOMA

Romano, A.; Puglisi, F.; Parrinello, N.L.; More

HemaSphere. 3(S1):622, June 2019.

Author:
La Nasa, G.
Author:
La Sala, E.

PF174 GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL

Chiaretti, S.; Cesini, L.; Di Raimondo, F.; More

HemaSphere. 3(S1):39, June 2019.

Author:
Laadem, A.

PB2260 THE JOURNEY PRO STUDY: FEASIBILITY AND USER ACCEPTANCE OF A SMARTPHONE APP TO ASSESS THE BURDEN OF ANEMIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), β-THALASSEMIA (BT), AND MYELOFIBROSIS (MF)

Pariseau, J.; Hu, X. H.; Mahmoud, D.; More

HemaSphere. 3(S1):1011, June 2019.

Author:
Laas, C.

PB1689 LEVELS OF BCL2 EXPRESSION AT POST-INDUCTION AND AT COMPLETE REMISSION IMPACT THE OUTCOME IN AML AND MAY IDENTIFY THOSE PATIENTS THAT WOULD BENEFIT OF BCL2 INHIBITORS

Bilbao, C.; Medina, C. Rodríguez; Sosa, S. Sánchez; More

HemaSphere. 3(S1):778, June 2019.

PB2233 RUXOLITINIB IN POLYCYTHEMIA VERA PATIENTS: RESPONSE DIFFERENCES BETWEEN IN HYDROXYUREA INTOLERANT AND RESISTANT PATIENTS

Pérez, E. González; FernándezFuertes, F.; Sánchez, J. M. Raya; More

HemaSphere. 3(S1):1001, June 2019.

Author:
Labopin, M.

S114 POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT

Nagler, A.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9, June 2019.

S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9-10, June 2019.

Author:
Labotka, R.

PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL – ANALYSIS FROM THE TOURMALINE-MM3 STUDY

Goldschmidt, H.; Dimopoulos, M.A.; Rajkumar, S.V.; More

HemaSphere. 3(S1):632-633, June 2019.

Author:
Labrador, G.

PF757 REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3(S1):332-333, June 2019.

Author:
Labrador, J.

PF216 ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL

Paiva, B.; Martínez-Cuadrón, D.; Bergua, J.M.; More

HemaSphere. 3(S1):59, June 2019.

PF555 PROGNOSTIC VALUE OF NEXT GENERATION FLOW MONITORING CIRCULATING TUMOR PLASMA CELLS IN PERIPHERAL BLOOD ON MYELOMA PATIENTS AFTER TREATMENT

Flores, L. Sanoja; Montero, J. Flores; Contreras-Sanfeliciano, T.; More

HemaSphere. 3(S1):230, June 2019.

PS1398 RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT

Dávila, J.; González-Calle, V.; Puig, N.; More

HemaSphere. 3(S1):641-642, June 2019.

Author:
Labrijn, A.
Author:
Labuhn, M.

PS998 JANUS KINASE AND CYTOKINE RECEPTOR MUTATIONS IN TRANSIENT ABNORMAL MYELOPOIESIS AND MYELOID LEUKEMIA IN CHILDREN WITH TRISOMY 21

Labuhn, M.; Perkins, K.; Papaemmanuil, E.; More

HemaSphere. 3(S1):449, June 2019.

S115 IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3(S1):9-10, June 2019.

Author:
LaCasce, A.

S867 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS

Advani, R.; Bartlett, N.; Smith, S.; More

HemaSphere. 3(S1):388, June 2019.

Author:
LaCasce, A.S.

PF374 IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE-ARM, MULTICENTER, PHASE 2 TRIAL

Davids, M.S.; Brander, D.M.; Kim, H.T.; More

HemaSphere. 3(S1):138-139, June 2019.

Author:
Lacayo, N.J.

PS940 COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA

Pullarkat, V.A.; Stock, W.; Lacayo, N.J.; More

HemaSphere. 3(S1):423-424, June 2019.

Author:
Lacerda, J.

PB2120 THE IMPACT OF DEPTH OF RESPONSE BEFORE AND AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA PATIENTS

Durão, S.; Vieira, J.; Velosa, F.; More

HemaSphere. 3(S1):954-955, June 2019.

Author:
Lachmann, H.

PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3(S1):958, June 2019.

Author:
Lachot, S.
Author:
Lacut, K.
Author:
Lacy, M.

PF625 VENETOCLAX FOR THE TREATMENT OF TRANSLOCATION (11; 14) AL AMYLOIDOSIS

Sidiqi, M.H.; Saleh, A.S. Al; Leung, N.; More

HemaSphere. 3(S1):265-266, June 2019.

PS1422 VENETOCLAX FOR THE TREATMENT OF MULTIPLE MYELOMA: OUTCOMES OUTSIDE OF CLINICAL TRIALS

Sidiqi, M.H.; Saleh, A.S. Al; Kumar, S.; More

HemaSphere. 3(S1):654-655, June 2019.

Author:
Lad, D.P.

PF498 A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL TRIAL OF DAILY VERSUS ALTERNATE DAY ORAL IRON IN TREATMENT OF IRON DEFICIENCY ANEMIA

Lad, D.P.; Kaundal, R.; Bhatia, P.; More

HemaSphere. 3(S1):201-202, June 2019.

Author:
Ladab, S.
Author:
Ladaique, A.

PS1410 DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT

Gounot, R.; Lemonnier, F.; Dupuis, J.; More

HemaSphere. 3(S1):648, June 2019.

Author:
Laddaga, F.E.
Author:
Ladeb, S.
Author:
Ladetto, M.

PS1248 COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL

Ferrero, S.; Zaccaria, G.M.; Barbero, D.; More

HemaSphere. 3(S1):569-570, June 2019.

PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK

Drandi, D.; Alcantara, M.; Barbero, D.; More

HemaSphere. 3(S1):599, June 2019.

Author:
Ladikou, E.
Author:
Ladislau, L.
Author:
Ladogana, S.
Author:
Ladygina, E.

PS1104 EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION

Melikyan, A.; Egorova, E.; Pustovaya, E.; More

HemaSphere. 3(S1):500, June 2019.

Author:
Laetsch, T.W.

S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES

Grupp, S.; Maude, S.; Baruchel, A.; More

HemaSphere. 3(S1):746-747, June 2019.

PB1938 PERSPECTIVE OF THE PATIENT WITH CML AND FAILURE TO TREATMENT WITH IMATINIB AT AN ENVIROMENT OF LIMITED RESOURCES.

Osorno-Rodríguez, K.L.; Cantú-Rodriguez, O.G.; Gómez-Villarreal, J.P.; More

HemaSphere. 3(S1):881, June 2019.

Author:
Lafaurie, M.
Author:
Laffan, M.

S889 GRANULOCYTES AND MONO-NUCLEAR CELLS FROM PATIENTS WITH MYELOPROLIFERATIVE DISORDERS HARBOUR PERSISTENT EVIDENCE OF DNA DAMAGE AND TP53 PATHWAY ACTIVATION THAT CORRELATES WITH JAK-STAT ACTIVATION

Innes, A.; Robinson, M.; Gerrard, G.; More

HemaSphere. 3(S1):400, June 2019.

Author:
Lafrance, W.
Author:
Lagarde, S.

PF151 RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL

Laurent, A.P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3(S1):28, June 2019.

Author:
Lagarkova, M.

PS1315 CHANGES IN THE SECRETOME COMPOSITION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA WITHOUT BONE MARROW INVOLVEMENT

Petinati, N.; Shender, V.; Shnaider, P.; More

HemaSphere. 3(S1):600-601, June 2019.

PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

Soverini, S.; Martelli, M.; Bavaro, L.; More

HemaSphere. 3(S1):37-38, June 2019.

Author:
Lagreca, I.

PS1274 EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3(S1):583, June 2019.

Author:
Lagrou, K.

PS1283 CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) – A MULTICENTER STUDY

Cornely, O.A.; Seidel, D.; Arenz, D.; More

HemaSphere. 3(S1):587, June 2019.

Author:
Laguna, P.
Author:
Lahav, M.
Author:
Lahoz, C.
Author:
Lahr, C.
Author:
Lahuerta, J.-J.

S121 SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3(S1):12-13, June 2019.

S871 CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3(S1):390, June 2019.

PS1348 DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM)

Pérez, C.; Botta, C.; Zabaleta, A.; More

HemaSphere. 3(S1):615-616, June 2019.

Author:
Lahuerta, J.J.

PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Rosiñol, L.; Hebraud, B.; Oriol, A.; More

HemaSphere. 3(S1):249-250, June 2019.

PF609 HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3(S1):258, June 2019.

PS1351 CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL

Ubieto, A. Jiménez; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3(S1):617, June 2019.

PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

Puig, N.; Paíno, T.; Pérez, J.J.; More

HemaSphere. 3(S1):617-618, June 2019.

PB1981 RESULTS OBTAINED FROM CLINICAL TRIALS PHASE I/II IN HEMATOLOGICAL MALIGNANCIES. CLINICAL EXPERIENCE OF A SINGLE CENTER: HOSPITAL 12 OCTUBRE.

Cuéllar Pérez-Ávila, C.; Alonso Fernández, R.; Ayala Díaz, R.; More

HemaSphere. 3(S1):899, June 2019.

Author:
Lai, Y.-H.
Author:
Lai, Y.-Y.
Author:
Laille, E.

PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS

Babiker, H.; Milhem, M.; Aisner, J.; More

HemaSphere. 3(S1):799, June 2019.

Author:
Laina, A.

PS1394 FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA

Kastritis, E.; Laina, A.; Gavriatopoulou, M.; More

HemaSphere. 3(S1):639-640, June 2019.

Author:
Lainé, D.

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

Liles, D.; Shah, N.; Scullin, B.; More

HemaSphere. 3(S1):380-381, June 2019.

Author:
Lainey, E.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

Author:
Lak, N.